
|Videos|November 3, 2021
Oral testosterone undecanoate shows promising results for first use in the real world
Author(s)Urology Times staff
“We were surprised to see that the majority of subjects in these simulations had testosterone levels within eugonadal range for all 3 dose's studies,” says Jay Newmark, MD, MBA.
Advertisement
In this video, Jay Newmark, MD, MBA, discusses the background, findings, and takeaways of the study, “Real-World Experience with First FDA-Approved Oral Testosterone Undecanoate Formulation,” presented recently at the 2021 Sexual Medicine Society of North America Fall Scientific Meeting. Newmark is a chief medical officer at Clarus Therapeutics, Northbrook, Illinois.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Study launches of MRI plus PSMA-PET imaging for prostate cancer detection
2
CREST and POTOMAC: Redefining immunotherapy’s role in NMIBC
3
Practical uses of AI across the urologic care continuum
4
How to manage bladder symptoms that fluctuate with your cycle
5



















